Organization
The Lymphoma Academic Research Organisation
16 clinical trials
Clinical trial
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven MaintenanceStatus: Active (not recruiting), Estimated PCD: 2019-03-01
Clinical trial
Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapseStatus: Not yet recruiting, Estimated PCD: 2026-01-15
Clinical trial
A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular LymphomaStatus: Recruiting, Estimated PCD: 2028-11-01
Clinical trial
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2022-04-19
Clinical trial
A Multicentre, Phase II, Open Label, Single Arm Study of Pixantrone in Patients With CD20-positive Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated With Rituximab, Ifosfamide and Etoposide.Status: Active (not recruiting), Estimated PCD: 2019-06-15
Clinical trial
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2020-11-30
Clinical trial
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyStatus: Active (not recruiting), Estimated PCD: 2023-01-10
Clinical trial
Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-02-10
Clinical trial
A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell LymphomaStatus: Completed, Estimated PCD: 2013-07-01
Clinical trial
Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOPStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell LymphomaStatus: Completed, Estimated PCD: 2018-07-11
Clinical trial
Phase II, Open-Label Study Evaluating Efficacy of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or OlderStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01